670 related articles for article (PubMed ID: 18413790)
1. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.
Bonfils C; Kalita A; Dubay M; Siu LL; Carducci MA; Reid G; Martell RE; Besterman JM; Li Z
Clin Cancer Res; 2008 Jun; 14(11):3441-9. PubMed ID: 18519775
[TBL] [Abstract][Full Text] [Related]
3. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
[TBL] [Abstract][Full Text] [Related]
4. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group.
Beckers T; Burkhardt C; Wieland H; Gimmnich P; Ciossek T; Maier T; Sanders K
Int J Cancer; 2007 Sep; 121(5):1138-48. PubMed ID: 17455259
[TBL] [Abstract][Full Text] [Related]
5. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.
Arts J; Angibaud P; Mariën A; Floren W; Janssens B; King P; van Dun J; Janssen L; Geerts T; Tuman RW; Johnson DL; Andries L; Jung M; Janicot M; van Emelen K
Br J Cancer; 2007 Nov; 97(10):1344-53. PubMed ID: 18000499
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
7. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Buglio D; Mamidipudi V; Khaskhely NM; Brady H; Heise C; Besterman J; Martell RE; MacBeth K; Younes A
Br J Haematol; 2010 Nov; 151(4):387-96. PubMed ID: 20880107
[TBL] [Abstract][Full Text] [Related]
8. Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor.
Le Tourneau C; Siu LL
Expert Opin Investig Drugs; 2008 Aug; 17(8):1247-54. PubMed ID: 18616420
[TBL] [Abstract][Full Text] [Related]
9. CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo.
Cao ZA; Bass KE; Balasubramanian S; Liu L; Schultz B; Verner E; Dai Y; Molina RA; Davis JR; Misialek S; Sendzik M; Orr CJ; Leung L; Callan O; Young P; Dalrymple SA; Buggy JJ
Mol Cancer Ther; 2006 Jul; 5(7):1693-701. PubMed ID: 16891455
[TBL] [Abstract][Full Text] [Related]
10. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.
Buggy JJ; Cao ZA; Bass KE; Verner E; Balasubramanian S; Liu L; Schultz BE; Young PR; Dalrymple SA
Mol Cancer Ther; 2006 May; 5(5):1309-17. PubMed ID: 16731764
[TBL] [Abstract][Full Text] [Related]
11. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
12. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
[TBL] [Abstract][Full Text] [Related]
13. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
14. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
15. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
Kakihana M; Ohira T; Chan D; Webster RB; Kato H; Drabkin HA; Gemmill RM
J Thorac Oncol; 2009 Dec; 4(12):1455-65. PubMed ID: 20009910
[TBL] [Abstract][Full Text] [Related]
16. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
[TBL] [Abstract][Full Text] [Related]
17. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.
Hassig CA; Symons KT; Guo X; Nguyen PM; Annable T; Wash PL; Payne JE; Jenkins DA; Bonnefous C; Trotter C; Wang Y; Anzola JV; Milkova EL; Hoffman TZ; Dozier SJ; Wiley BM; Saven A; Malecha JW; Davis RL; Muhammad J; Shiau AK; Noble SA; Rao TS; Smith ND; Hager JH
Mol Cancer Ther; 2008 May; 7(5):1054-65. PubMed ID: 18483295
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
Lu YS; Kashida Y; Kulp SK; Wang YC; Wang D; Hung JH; Tang M; Lin ZZ; Chen TJ; Cheng AL; Chen CS
Hepatology; 2007 Oct; 46(4):1119-30. PubMed ID: 17654699
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
20. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.
Zhou N; Moradei O; Raeppel S; Leit S; Frechette S; Gaudette F; Paquin I; Bernstein N; Bouchain G; Vaisburg A; Jin Z; Gillespie J; Wang J; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Lu A; Rahil J; MacLeod AR; Li Z; Besterman JM; Delorme D
J Med Chem; 2008 Jul; 51(14):4072-5. PubMed ID: 18570366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
